18 October 2021 ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
13 October 2021 ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at ECTRIMS-2021
22 September 2021 ORYZON to present new clinical data and corporate updates at international conferences in September and October
21 September 2021 Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat
13 July 2021 ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia
9 July 2021 ORYZON presents safety and efficacy data of vafidemstat from the Phase II ESCAPE trial in severe CoVID-19 patients at ECCMID-2021
21 June 2021 ORYZON to present new clinical data and corporate updates at international conferences in June and July
15 June 2021 ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
11 June 2021 ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML